Literature DB >> 24979654

Efficacy of continuation/maintenance electroconvulsive therapy for the prevention of recurrence of a major depressive episode in adults with unipolar depression: a systematic review.

E Denise Brown1, How Lee, Daniel Scott, Greta G Cummings.   

Abstract

OBJECTIVE: Divergent opinion surrounds the use of continuation/maintenance electroconvulsive therapy (c/mECT) as a recurrence prevention strategy in depression because of limited data on efficacy and adverse effects. In an effort to synthesize what is known about its efficacy, a systematic review of controlled studies reporting efficacy of c/mECT for the prevention of relapse or recurrence of a depressive episode in adults with unipolar major depression was conducted.
METHODS: Eleven electronic databases were searched with a 3-stage screening process conducted by the author with an independent review. Quality assessments and data extractions were performed on selected studies using preselected tools.
RESULTS: Six studies met the inclusion criteria; these are as follows: 3 randomized controlled trials, 1 small nonrandomized controlled trial, and 2 retrospective chart reviews. All participants had undergone an index course of electroconvulsive therapy with positive effects before receiving c/mECT or control/comparison interventions. One randomized controlled trial and retrospective chart review showed no significant difference between c/mECT and control/comparison interventions; the remaining 4 studies showed a significantly superior effect of c/mECT for the prevention of recurrence of depression. Monotherapy of c/mECT was less efficacious than c/mECT in combination with antidepressant medication, as was c/mECT delivered on a schedule, which was unresponsive to early signs of recurrence.
CONCLUSIONS: This review suggests that c/mECT is efficacious for the prevention of relapse/recurrence of major depression and that efficacy is increased when c/mECT is provided in combination with antidepressant medication and at flexible treatment intervals, responsive to early signs of recurrence.

Entities:  

Mesh:

Year:  2014        PMID: 24979654     DOI: 10.1097/YCT.0000000000000085

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  5 in total

1.  Electroconvulsive therapy: a life course approach for recurrent depressive disorder.

Authors:  Sarah Carney; Musa Basseer Sami; Victoria Clark; Kompancariel Kuruvilla Kuruvilla
Journal:  BMJ Case Rep       Date:  2015-05-24

2.  Electroconvulsive Therapy Practice in the Province of Quebec: Linked Health Administrative Data Study from 1996 to 2013.

Authors:  Morgane Lemasson; Julie Haesebaert; Louis Rochette; Eric Pelletier; Alain Lesage; Simon Patry
Journal:  Can J Psychiatry       Date:  2017-10-25       Impact factor: 4.356

3.  Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic.

Authors:  Simon Lambrichts; Kristof Vansteelandt; Bo Crauwels; Jasmien Obbels; Eva Pilato; Jonas Denduyver; Katrien Ernes; Pieter-Paul Maebe; Charlotte Migchels; Lore Roosen; Satya Buggenhout; Filip Bouckaert; Didier Schrijvers; Pascal Sienaert
Journal:  Acta Psychiatr Scand       Date:  2021-06-28       Impact factor: 7.734

4.  Lorazepam provocation test in purported schizophrenia with lack of treatment response.

Authors:  John E Berg
Journal:  Ment Illn       Date:  2014-12-18

5.  P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy.

Authors:  Alexandra Neyazi; Wiebke Theilmann; Claudia Brandt; Tomi Rantamäki; Nobuaki Matsui; Mathias Rhein; Johannes Kornhuber; Malek Bajbouj; Wolfgang Sperling; Stefan Bleich; Helge Frieling; Wolfgang Löscher
Journal:  Transl Psychiatry       Date:  2018-01-22       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.